Peer-reviewed veterinary case report
Oxidative stress in dogs with Cushing syndrome improves
By Chen, Hong et al.·Published in American journal of veterinary research·2025·College of Veterinary Medicine, China·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Canine Cushing syndrome elevates oxidative stress that is attenuated by trilostane.
- Species:
- dog
Plain-English summary
A group of dogs diagnosed with Cushing's disease (hyperadrenocorticism) showed high levels of oxidative stress, which can harm their health. After being treated with trilostane, a medication commonly used for this condition, their oxidative stress levels improved significantly. The dogs had lower markers of oxidative stress after 45 days of treatment, indicating that trilostane helped reduce the harmful effects of the disease. This suggests that trilostane not only helps manage Cushing's symptoms but also supports overall health by reducing oxidative stress.
People also search for: dog Cushing's disease treatment · trilostane for dogs · high oxidative stress in dogs
Abstract
OBJECTIVE: To evaluate oxidant-antioxidant status in hyperadrenocorticism (HAC) dogs at diagnosis and after trilostane (Adrestan). METHODS: This study, conducted from June 2024 through March 2025, enrolled 25 dogs with HAC and 21 healthy control dogs. Serum malondialdehyde (MDA) concentration, superoxide dismutase (SOD) activity, total oxidant status (TOS), total antioxidant capacity (TAC), and oxidative stress index (OSI) were analyzed before and after treatment. RESULTS: The study included 25 dogs with HAC (14 treated with trilostane, 1 mg/kg, twice daily for 45 days) and 21 healthy controls. At baseline, HAC dogs had significantly elevated oxidative stress markers (MDA, 10.28 μmol/L; TOS, 35.68 μmol H2O2 equivalent (Equiv)/L; OSI, 4.60 arbitrary units (AU)) compared to controls, whereas SOD (44.77 U/mL) and TAC (0.96 mmol/L) remained similar. After trilostane treatment, oxidative stress significantly improved, including decreases in MDA (7.91 → 4.28 μmol/L), TOS (30.82 → 17.85 μmol H2O2 Equiv/L), and OSI (3.61 → 2.14 AU); increased SOD (46.25 → 56.06 U/mL nonsignificant); but no change in TAC (0.97 → 0.94 mmol/L). CONCLUSIONS: These findings demonstrated elevated oxidative stress in HAC dogs that was effectively ameliorated by trilostane. CLINICAL RELEVANCE: This study first provides comprehensive documentation of oxidative stress in dogs with HAC and its mitigation after trilostane treatment. Significant oxidative imbalance in canine HAC supports monitoring redox parameters as part of disease management.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/41043486/